FOLR-1
Alternative name:
folate receptor alpha
Methodology
Immunohistochemistry (IHC)
Test Description and clinical significance
Disease:
epithelial ovarian cancer (EOC)
FOLR1 (FOLR1-2.1) RxDx Assay is the first and only immunohistochemistry (IHC) assay FDA approved to identify epithelial ovarian cancer (EOC) patients eligible for FOLR1-targeted treatment with ELAHERE (mirvetuximab soravtansine).
Specimen Requirements
Collection:
FFPE/un-stained slides/Fresh tissue in formalin
Stability:
Room temperature
Unacceptable Conditions:
Unlabeled specimen/specimen left unfixed
for extended periods
Storage & Transport
Room Temperature
New York Approved
NO
TAT
48 hours
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
